BrainsWay
16 Hartum St Har Hotzvim, Jerusalem, 9777516, Israel
Overview
Brainsway's patented breakthrough technology launches a new era in brain disorder treatment. A non-invasive, yet highly effective solution, Brainsway can make a difference in the wellbeing and health of millions of patients worldwide. Brainsway's technology releases millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. Brainsway's treatment was approved by the FDA for Major Depressive Disorder patients*. The technology is also safe, with no systemic effects or long-term side effects, and highly convenient, requiring only brief daily sessions over a couple of weeks. Brainsway's technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials performed. Brainsway technology is based on a patent registered by the U.S. National Institutes of Health (NIH). Brainsway is dedicated to research and continuously explores treatments for a variety of brain disorders.
- Total investments
- 3
- Lead investments
- 3
- Investments · 12mo
- 3
- Active investors
- 8
Sector focus
- Biotechnology
- Health Care
- Life Science
Investment portfolio
- Radial
Led · Series A · Jul 2026
Radial Health develops the clinical infrastructure, reimbursement tools, and an AI-guided decision support platform to support delivery of Brain Medicine treatments, including non-invasive therapies such as Deep TMS. The company operates as a management services organization for a network of Brain Medicine clinics and is building a national platform for advanced mental health care. Radial is using capital from its Series A syndicate to expand its clinical footprint, strengthen its technology platform, and increase patient access to evidence-based Brain Medicine treatments. The financing is also intended to support Radial's exploration of M&A opportunities. Investors in the company’s recent financing include BrainsWay, General Catalyst, Floating Point Capital, Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and Diede van Lamoen.
- Hopemark Health
Led · Equity · May 2026
Hopemark Health delivers integrated outpatient psychiatric care through a multidisciplinary team of psychiatrists, therapists, psychiatric nurse practitioners, physician assistants, and support staff. Founded in 2016 by Dr. Abid Nazeer, the company operates multiple clinics in the greater Chicago area and has completed thousands of treatments for patients with mental health and substance use disorders. Hopemark is noted for its work in ketamine-based therapies and evidence-based treatment programs. The company’s recent minority investment from BrainsWay provides growth capital and an operational partnership to help scale clinic access. Hopemark’s clinical operations are positioned to expand access to interventional psychiatry modalities alongside its existing services.
- Neurolief
Led · Equity · Mar 2026
Neurolief develops non-invasive neuromodulation therapies and is focused on delivering clinically validated treatments that expand access to care. Its lead product, Proliv™Rx, received FDA Premarket Approval in December 2025 as the first FDA-approved prescription, at-home brain neuromodulation system for adults with major depressive disorder who have not achieved adequate response to at least one antidepressant. Proliv™Rx is prescribed and supervised by physicians while being self-administered by patients at home, intended to overcome access barriers tied to clinic-dependent delivery models. Following FDA approval, Neurolief reported early commercial traction and is using recent investment to accelerate U.S. rollout and scale its at-home therapy model. The company framed its strategy around bridging care gaps and supporting health systems shifting toward value-based care.